Preview

Нефрология

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Только для подписчиков

Хронический гепатит С: современное состояние проблемы

https://doi.org/10.24884/1561-6274-2019-23-4-36-46

Полный текст:

Аннотация

Хронический гепатит С (ХГС) является одной из распространенных хронических вирусных инфекций. Современные достижения в терапии ХГС позволили ВОЗ разработать Глобальную стратегию сектора здравоохранения по вирусному гепатиту на 2016-2021 гг с целью его элиминации к 2030 г. Противовирусные препараты новых поколений обладают терапевтической эффективностью более 98% и широкими показаниями для применения. В то же время, имеются особые группы пациентов, у которых ограничен выбор схемы противовирусной терапии и отличается ее эффективность от общей популяции больных ХГС. В обзорной статье приводятся данные об эпидемиологии, патогенезе, клинических проявлениях ХГС и современных подходах к терапии заболевания. Особое внимание уделено больным с внепеченочными проявлениям хронической ВГС-инфекции.

Об авторах

Д. А. Лиознов
Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова; Научно-исследовательский институт гриппа им. А.А. Смородинцева
Россия

Лиознов Дмитрий Анатольевич - доктор медицинских наук, заведующий кафедрой инфекционных болезней и эпидемиологии, доктор медицинских наук, доцент ПСПбГМУ им. акад. И.П. Павлова; заместитель директора по научной работе НИИ гриппа им. А.А. Смородинцева.

197022, Санкт-Петербург, ул. Л. Толстого, д. 6/8, Тел.: (812) 338-60-40; 197376, Санкт-Петербург, улица профессор Попова, д. 15/17



Н. В. Дунаева
Центр по профилактике и борьбе со СПИД и инфекционными заболеваниями
Россия

Дунаева Наталья Викторовна - кандидат медицинских наук, доцент, заведующая отделением соматической патологии.

190103, Санкт-Петербург, наб. Обводного канала, д. 179. Тел.: +7-921-741-88-20



Н. Х. Чунг
Медицинский и фармацевтический университет
Россия

Чунг Нгуен Хыу - ассистент кафедры внутренних болезней, заочный аспирант Научно-исследовательского института эпидемиологии и микробиологии им. Пастера.

Хошимин, ул. Хонг Банг, д. 217, Тел.: (+84) 37-67-68-616



О. В. Горчакова
Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова
Россия

Горчакова Ольга Владимировна - кандидат медицинских наук, научный сотрудник лаборатории хронических вирусных инфекций НИЦ, ассистент кафедры инфекционных болезней и эпидемиологии.

197022, Санкт-Петербург, ул. Л. Толстого, д. 6/8, Тел.: +7(812)338-70-58



Т. В. Антонова
Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова
Россия

Антонова Тамара Васильевна - доктор медицинских наук, профессор, кафедра инфекционных болезней и эпидемиологии.

197022, Санкт-Петербург, ул. Л. Толстого, д. 6/8, Тел.: +7(812)338-70-58



Список литературы

1. WHO. Global hepatitis report 2017 [Электронный ресурс]. - 2017. - Режим доступа: http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/

2. Blach, S, Zeuzem S, Manns M et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The Lancet Gastroenterology & Hepatology 2016; 2 (3): 161-176

3. Lavenchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-115

4. Everson GT, Towner WJ, Davis VN et al. Sofosbuvir With Vel-patasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized. Ann Intern Med 2015; 163 (11): 818-826

5. Bjoerkvoll B, Viet L, OI HS et al. Screening test accuracy among potential blood donors of HBsAg, anti-HBc and anti-HCV to detect hepatitis B and C virus infection in rural Cambodia and Vietnam. Southeast Asian. J Trop Med Public Health 2010; 41 (5): 1127-1135

6. Cavalcante LN, Lyra AC. Predictive factors associated with hepatitis C antiviral therapy response. World Journal of Hepatology 2015; 7 (12): 1617-1631

7. Kayali Z, Schmidt WN. Finally sofosbuvir: an oral anti-HCV drug with wide performance capability. Pharmacogenomics and Personalized Medicine 2014; 7: 387-398

8. Rao VB, Johari N, du Cros P et al. Hepatitis C serop-revalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis 2015; 15 (7): 819-824

9. Anderson JC, Simonetti J, Fisher DG et al. Comparison of different HCV viral load and genotyping assays. J Clin Virol 2003; 28 (1): 27-37

10. Simmonds P, Bukh J, Combet C et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42 (4): 962-973

11. Smith DB, Bukh J, Kuiken C et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014; 59 (1): 318-327

12. Murphy DG, Willems B, Deschenes M et al. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5’ untranslated region sequences. J Clin Microbiol 2007; 45 (4): 1102-1112

13. Murphy DG, Sablon E, Chamberland J et al. Hepatitis C virus genotype 7, a new genotype originating from Central Africa. J Clin Microbiol 2015; 53 (3): 967-972

14. Messina JP, Humphreys I, Flaxman A et al. Global Distribution and Prevalence of Hepatitis C Virus Genotypes. Hepatology 2015; 61 (1): 77-87

15. Чуланов ВП, Пименов НН, Мамонова НА и др. Хронический гепатит С как проблема здравоохранения России сегодня и завтра. Терапевтический архив 2015; 11: 5-10

16. Пименов НН, Вдовин АВ, Комарова СВ и др. Актуальность и перспективы внедрения в России единого федерального регистра больных вирусными гепатитами В и С. Терапевтический архив; 2013(11): 4-9

17. Козлов ВК, бельмах ВВ, Радченко ВГ. HCV- инфекция: Современная стратегия комплексного лечения. Пособие для врачей. СПБ, Диалект, 2008; 80

18. Лобзин ЮВ. Вирусные гепатиты, СПБ.: Фолиант, 1999; 104

19. Нечаев ВВ, Иванов АК, Пантелеев АМ. Социальнозначимые инекции. Часть I. Моноинекции: туберкулез, ВИЧ-инекция, вирусные гепатиты, СПБ.: ООО «Береста», 2011; 439

20. Жданов КВ, Лобзин ЮВ, Гусев ДА, Козлов КВ. Вирусные гепатиты, СПб.: Фолиант, 2011; 304

21. Серова ВВ, Апросина ЗГ. Хронический вирусный гепатит, Москва: Медицина, 2004; 384 [Serov VV, Aprosina ZG. Chronic viral hepatitis, Moscow: Medicine, 2004; 384]

22. Franco S, Barcons MG, BasagoitiFP et al. Characterization and evolution of NS5A quasispecies of hepatitis C virus genotype 1b in patients with different stages of liver disease. Journal of Medical Virology 2003, 71: 195-204

23. Lee MH, Yang HI, Lu SN et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012; 206 (4): 469-477

24. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J ViralHepat 2006; 13 (1): 34-41

25. Rehermann B, Bertoletti A. Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. J Hepatol 2015; 61 (2): 712-721

26. Kao JH, Ahn SH, Chien RN et al. Urgency to treat patients with chronic hepatitis C in Asia. J Gastroenterol Hepatol 2017; 32(5): 966-974. doi: 10.1111/jgh.13709

27. Rachel HW, Dusheiko G. Natural history of hepatitis C. Journal of Hepatology 2014; 61: 58-68

28. Kiyosawa K, Tanaka E, Sodeyama T, Furuta S. Natural History of Hepatitis C. Intervirology 1994; 37: 101-107

29. Mauss S, Rockstroh J, Wedemeyer H et al. Hepatology - A Clinical text book, 8-е изд., перераб. и доп., Hamburg: Medizin Fokus Verlag, 2017; 729

30. Bartenschlager R, Baumert TF, Bukh J et al. Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. Virus Research 2018; 248: 53-62

31. de Groen RA. Understanding the Innate Immune Response in Viral Hepatitis: Interferons and NKCells [Электронный ресурс] Erasmus University Rotterdam, 2017; Режим доступа: http://hdl.handle.net/1765/101848

32. Ishii S, Koziel MJ. Immune responses during acute and chronic infection with hepatitis C virus. Clinical immunology 2008; 128 (2): 133-147

33. Burke KP, Cox AL. Hepatitis C Virus Evasion of Adaptive Immune Responses- A Model for Viral Persistence. Immunologic research 2010; 47 (1): 216-227

34. Ascione A, Tartaglione T, Di Costanzo GG. Natural history of chronic hepatitis C virus infection. Dig Liver Dis 2007; 39(Suppl): S4-S7

35. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26: 34S-38S

36. Fattovich G, Giustina G, Degos F et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective followup study of 384 patients. Gastroenterology 1997; 112: 463-472

37. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349 (9055): 825-832

38. Planas R, Balleste B, Alvarez MA et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004; 40 (5): 823-830

39. Missiha SB, Ostrowski M, Heathcote EJ. Disease Progression in Chronic Hepatitis C: Modifiable and Nonmodifiable Factors. Gastroenterology 2008; 134 (6): 1699-1714

40. Sarin SK, Kumar M. Natural history of HCV infection. Hepatol Int 2012; 6 (4): 684-695

41. Cadieux G, Campbell J, Dendukuri N. Systematic review of the accuracy of antibody tests used to screen asymptomatic adults for hepatitis C infection. CMAJ Open 2016; 4(4): E737-E745

42. Fierer DS, Dieterich DT, Mullen MP et al. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis 2014; 58 (6): 873-879

43. Ha S, Totten S, Pogany L, Wu J, Gale-Rowe M. Hepatitis C in Canada and the importance of risk-based screening. Can Commun Dis Rep 2016; 42(3): 57-62

44. Mitchell AE, Colvin HM, Palmer R. Beasley Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology 2010; 51 (3): 729-733

45. Papatheodoridis GV, Tsochatzis E, Hardtke S, Wedemeyer H. Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review. Liver Int 2014; 34 (10): 1452-1463

46. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nature medicine 2013; 19(7): 850-858

47. Жевнерова CK Антонова ТВ, Ковалева ВА. Клиниколабораторная характеристика хронического гепатита С на ранних сроках развития. Ученые записки Санкт-Петербургского государственного медицинского университета им. акад. И.П. Павлова 2016; 23 (4): 45-49

48. Соринсон СН. Вирусные гепатиты. СПБ.: Теза, 1997, 326 [48. Sorinson CH. Viral hepatitis. SPB.: Teza, 1997, 326]

49. Sherman AC, Sherman KE. Extrahepatic manifestations of hepatitis C infection: navigating CHASM. Curr HIV/AIDS Rep 2015; 12(3): 353-361

50. Wong W, Denton M, Rennke HG, Lin J. Hepatitis C, proteinuria and renal insufficiency. Am J of Kidney Dis 2004; 44(5): 924-929

51. Милованова СЮ, Лопаткина ТН, Козловская ЛВ, Краснова ТН. Моноклональные антитела к В-лимфоцитам (ритуксимаб) в лечении HCV-ассоциированного криоглобули-немическогогломерулонефрита тяжелого течении. Тер архив 2007; 6: 69-72

52. Смирнов АВ, Добронравов ВА, Сиповский ВГ и др. Случай криоглобулинемического гломерулонефрита при гепатите С. Нефрология 2007; 11 (4): 99-103

53. Смирнов АВ, Трофименко ИИ. Быстропрогрессирующий нефритический синдром у пациентки с криоглобу-линемическим васкулитом, ассоциированным с хроническим вирусным гепатитом. Нефрология 2010; 14 (1): 104-112

54. Смирнов АВ, Добронравов ВА, Каюков ИГ. Кардиоренальный континуум: патогенетические основы превентивной нефрологии. Нефрология 2005; 9 (3): 7-15

55. Roccatello D, Fornasieri A, Giachino O et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am JKidney Dis 2007; 49(1): 69-82

56. Добронравов ВА, Дунаева НВ. Поражение почек и хронический вирусный гепатит С. Нефрология 2008; 12(4): 9-19

57. Kupin WL. Viral-Associated GN: Hepatitis C and HIV. Clin J Am Soc Nephrol 2016;12(8):1337-1342

58. Medvedev R, Ploen D, Hildt E. HCV and Oxidative Stress: Implications for HCV Life Cycle and HCV-Associated Pathogenesis. Oxid Med Cell Longev 2016;2016:9012580

59. Tutal E, Sezer S, Ibis A, Bilgic A, Ozdemir N, Aldemir D, Haberal M. The influence of hepatitis C infection activity on oxidative stress markers and erythropoietin requirement in hemodialysis patients. Transplant Proc 2010 Jun;42(5):1629-1636

60. Arciello M, Gori M, Balsano C. Mitochondrial dysfunctions and altered metals homeostasis: new weapons to counteract HCV-related oxidative stress. Oxid Med Cell Longev2013;2013:971024

61. Mustafa M, Hussain S, Qureshi S et al. Study of the effect of antiviral therapy on homocysteinemia in hepatitis C virus- infected patients. BMC Gastroenterol 2012;12:117

62. Lim T Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy. Hepat Med 2014;6:113-118

63. Gonzalez-Reimers E, Quintero-Platt G, Mart in-Gonzalez C, Perez-Hernandez O, Romero-Acevedo L, Santolaria-Fernandez F. Thrombin activation and liver inflammation in advanced hepatitis C virus infection. World J Gastroenterol 2016 May 14;22(18):4427-4437

64. Лопаткина ТН. Новое в лечении хронических вирусных гепатитов [Электронный ресурс] Лечащий Врач 2007; 1. Режим доступа: https://www.lvrach.ru/2007/01/4534659

65. Anderson JP, Tchetgen EJ, Lo Re V et al. Antiretroviral Therapy Reduces the Rate of Hepatic Decompensation Among HIV- and Hepatitis C Virus-Coinfected Veterans. Clin Infect Dis 2014; 58: 719-727

66. van der Meer AJ, Veldt BJ, Feld JJ et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308 (24):2584-2593

67. Washington DC Twenty-Five Years of Progress Against Hepatitis C: Setbacks and Stepping Stones. PhRMA 2014: 20

68. Manns MP, Pockros PJ, Norkrans G et al. Long-term clearance of hepatitis C virus following interferon a-2b or peginterferon a-2b, alone or in combination with ribavirin. J Viral Hepat 2013: 20: 524-529

69. Swain MG, Lai MY, Shiffman ML et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139:1593-1601

70. Geddawy A, IbrahimYE, Elbahie NM,Ibrahim MA. Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction. Journal of Translational Internal Medicine 2017; 5 (1): 8-17

71. Marinho RT, Barreira DP. Hepatitis C, stigma and cure. World Journal of Gastroenterology 2013; 19(40):6703-6709

72. Wikto SZ, Scott JD. What is the impact of treatment for hepatitis C virus infection? / Lancet 2017; 390 (10090): 107-109

73. Friedman RM, Contente S. Treatment of Hepatitis C Infections with Interferon: A Historical Perspective. Hepatitis Research and Treatment 2010; 1: P. 1-4

74. Sen G. Viruses and interferons. Annual Review of Microbiology 2001; 55: 255-281

75. Hoofnagl JH, Mullen KD, Jones DB et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. N Engl J Med 1986; 315:1575-1578

76. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989; 321(22): 1501-1506

77. Di Bisceglie AM, Martin P, Kassianides C et al. Recombinant interferon alpha therapy for chronic hepatitis C: a randomized, double-blind, placebo controlled trial. N Engl J Med 1989; 321:1506-1510

78. Chen CH, Yu ML. Evolution of Interferon-Based Therapy for Chronic Hepatitis C [Электронный ресурс] Hepat Res Treat 2010: 2010. Режим доступа: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990099/

79. Feld, JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436 (7053):967-972

80. Satoh S, Mori K, Onomura D et al. Ribavirin suppresses hepatic lipogenesis through inosine monophosphate dehydrogenase inhibition: Involvement of adenosine monophosphate-activated protein kinase-related kinases and retinoid X receptor a. Hepatology Communications 2017; 1(6): 550-563

81. Bodenheimer HCJr, Lindsay KL, Davis GL et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26(2): 473-477

82. Dusheiko G, Main J, Thomas H et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled trial. J Hepatol 1996; 25,(5): 591-598

83. McHutchison JG, Everson GT, Gordon SC et al. nterferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492

84. Poynard T, Marcellin P, LeeSS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C. Lancet 1998; 352(9138):1426-1432

85. Heathcote EJ, Shiffman ML, Cooksley WG et al. Peginter-feron alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343(23): 1673-1680

86. Lindsay KL, Trepo C, Heintges T et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34(2): 395-403

87. Reddy KR, Wright TL, Pockros PJ et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33(2):433-438

88. Zeuzem, S, Feinman SV, Rasenack J et al. Peginter-feron alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343(23):1666-1672

89. Zeuzem S. Do differences in pegylation of interferon alfa matter? Gastroenterology 2010; 138(1):34-36

90. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347(13):975-982

91. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358(9286): 958-965

92. Pawlotsky JM, Roudot-Thoraval F, Bastie a et al. Factors effecting treatment responses to interferon-alpha in chronic hepatitis C. J Infect Dis 1996; 174(1): 1-7

93. Berg T, von Wagner M, Nasser S et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130(4):1086-1109

94. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005; 41: 275-279

95. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 2007;46:1688-1694

96. Davis GL, Wong JB, McHutchison JG et al.Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38: 645-652

97. Ferenci P, Fried MW, Shiffman ML et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin. J Hepatol 2005; 43: 425-433

98. Jensen DM, Morgan TR, Marcellin P et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43:954-960

99. Rosen H. Clinical practice. Chronic hepatitis C infection. N Engl J Med 2011;364(25):2429-2438

100. Hadziyannis SJ, Sette HJ, Morgan TR et al. Peginterferon alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140(5):346-355

101. Manns MP, Foster GR, Rockstroh JK. The way forward in HCV treatment - finding the right path. Nature Reviews Drug Discovery 2007;6:991-1000

102. EASL. Recommendations on Treatment of Hepatitis C 2014 / European Association for the Study of the Liver (EASL). J Hepatol 2014;61(2):373-395

103. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55(9):1350-1359

104. Ghany MG, Nelson DR, Strader DB et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver. Hepatology 2011; 54: 1433-1444

105. Hezode C, Forestier N, Dusheiko G et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-1850

106. Kwo PY Lawitz EJ, McCone J et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 triali. Lancet 2010; 376: 705-716

107. McHutchison JG, Everson GT, Gordon SC et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360:1827-1838

108. McHutchison JG, Manns MP, Muir AJ et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-1303

109. Poordad F, Bruno S, Manns MP et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206

110. Sherman KE, Flamm SL, Afdhal NH et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-1024

111. Hezode C. Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice. Liver International 2012; 32: 32-38

112. Maasoumy B, Port K, Markova AA et al. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One 2013; 8(2):e55285

113. Alexopoulou A, Karayiannis P. Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals. Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology 2015; 28(1):55-65

114. Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-1887

115. Schinazi RF, Shi J, Whitaker T. “Sofosbuvir (Sovaldi): The First-in-Class HCV NS5B Nucleotide Polymerase Inhibitor”. Innovative Drug Synthesis. / под общ. ред. J.J. Li, D.S. Johnson . NJ, USA: John Wiley & Sons 2015:341 с

116. Alberti A, Piovesan S. The evolution of the therapeutic strategy in hepatitis C: Features of sofosbuvir and indications. Digestive and Liver Disease 2014;46 (Suppl 5): S174-S178

117. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138(2): 447-462

118. Karageorgopoulos DE, El-Sherif O, Bhagani S, Khoo SH. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection. Curr Opin Infect Dis 2014; 27(1):36-45

119. Koff R. Review article: the efficacy and safety of sofos-buvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2014;39(5): 478-487

120. Gane EJ, Roberts SK, Stedman CA et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376:1467-1475

121. Alric L, Plaisier E, Thebault S et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J of Kidney Dis 2004 Apr; 43(4): 617-623

122. Дунаева НВ, Гезей МА, Колпащикова ЕЮ, и др. Опыт терапии пегилированным интерфероном альфа и рибавири-ном хронического гепатита С, осложненного развитием смешанной криоглобулинемии. Вестник НовГУ 2017;106(8):75-82

123. Игнатова ТМ, Козловская ЛВ, Гордовская НБ и др. Криоглобулинемический васкулит, ассоциированный с вирусом гепатита С: 20-летний опыт лечения. Терапевтический архив 2017;89(5):46-52

124. EASL Recommendations on Treatment of Hepatitis C 2015. European Association for the Study of the Liver. J of Hepatology 2015 Jul; 63(1): 199-236

125. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected withhepatitis C virus. Hepatology 2015 Sep;62(3):932-954

126. AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis 2018 Oct 30;67(10):1477-1492

127. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 2018 Aug;69(2):461-511

128. KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney International Supplements 2018;8:91-165

129. Дунаева НВ, Карев ВЕ, Воробьева ОА и др. Противовирусная терапия хронического гепатита С, осложненного системным криоглобулинемическим васкулитом. Журнал Ин-фектологии 2016;8(2):40-47

130. Li T, Qu X Guo X Wang X Wang L. Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis. Liver Int 2017 Jul;37(7):974-981

131. Munoz-Gomez R, Rincon D, Ahumada A et al. Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience. J ViralHepat 2017 Jun;24(6):464-471

132. Fernandez I, Munoz-Gomez R, Pascasio JM et al. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. J Hepatol 2017 Apr;66(4):718-723

133. Дунаева НВ, Колпащикова ЕЮ, Романова СЮ и др. Терапия препаратами прямого противовирусного действия хронического гепатита С, осложненного развитием смешанной криоглобулинемии. Журнал Инфектологии 2018;10(4):53-63

134. Santoriello D, Pullela NK, Uday KA, et al. Persistent Hepatitis C Virus-Associated Cryoglobulinemic Glomerulonephritis in Patients Successfully Treated With Direct-Acting Antiviral Therapy. Kidney Int Rep 2018 Apr 10;3(4):985-990

135. Suda G, Ogawa K, Morikawa K, Sakamoto N. Treatment of hepatitis C in special populations. J Gastroenterol 2018 May;53(5):591-605

136. Corson M, Moch A, Saab S. Hepatitis C Virus Treatment in Patients With Chronic Kidney Disease and in Kidney Transplant Recipients. Gastroenterol Hepatol (N Y) 2018 May;14(5):280-285

137. Goldberg DS, Abt PL, Reese PP; THINKER Trial Investigators. Transplanting HCV-Infected Kidneys into Uninfected Recipients. N Engl J Med 2017 Sep 14;377(11):1105

138. Kamalkiran M, Ravikiran V, Shashidhar C, Prasad KVR, Yeldandi V. Kidney Transplantation from a Hepatitis C Virus-positive Donor to a Hepatitis C Virus-negative Recipient. Indian J Nephrol 2018 Nov-Dec;28(6):488-489

139. Durand CM, Bowring MG, Brown DM et al. Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial. Ann Intern Med 2018 Apr 17;168(8):533-540

140. Reese PP, Abt PL, Blumberg EA et al. Twelve-Month Outcomes After Transplant of Hepatitis C-Infected Kidneys Into Uninfected Recipients: A Single-Group Trial. Ann Intern Med2018 Sep 4;169(5):273-281

141. Eckman MH, Woodle ES, Thakar CV, Paterno F, Sherman KE. Transplanting Hepatitis C Virus-Infected Versus Uninfected Kidneys Into Hepatitis C Virus-Infected Recipients: A Cost-Effectiveness Analysis. Ann Intern Med 2018 Aug 21;169(4):214-223.


Для цитирования:


Лиознов Д.А., Дунаева Н.В., Чунг Н.Х., Горчакова О.В., Антонова Т.В. Хронический гепатит С: современное состояние проблемы. Нефрология. 2019;23(4):36-46. https://doi.org/10.24884/1561-6274-2019-23-4-36-46

For citation:


Lioznov D.A., Dunaeva N.V., Chung N.H., Gorchakova O.V., Antonova T.V. Chronic hepatitis C: modern condition of the problem. Nephrology (Saint-Petersburg). 2019;23(4):36-46. (In Russ.) https://doi.org/10.24884/1561-6274-2019-23-4-36-46

Просмотров: 47


ISSN 1561-6274 (Print)
ISSN 2541-9439 (Online)